By Julian Richard, Benzinga
BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome with another patent notice of allowance from the United States Patent Office, adding to its already 19 issued patents under the ThermoStem® patent family. BioRestorative’s ThermoStem® program is a novel cell-based therapy program using cells that have metabolic activity, that once transplanted may be able to regulate the bodies metabolic homeostasis (balance) and potentially induce weight loss and a better metabolic state.
Metabolic syndrome is a cluster of conditions, such as obesity often times resulting in elevated cholesterol (fat) and glucose levels in the blood, these conditions increase the risk of developing type 2 diabetes, heart disease and stroke.
Pioneering research conducted by Biorestorative Therapies demonstrated that brown tissue burns rather than stores energy. This work was published in Stem cells and was performed in a collaboration with the University of Utah. Increased levels of brown tissue support weight loss by increasing metabolism and reducing glucose and cholesterol in the blood. Thus, increasing brown fat levels and activity may be a powerful way to treat metabolic syndrome's significant mortality and morbidity.
The ThermoStem® program is unique in that it pioneers the use of cell-based therapy to treat a global unmet medical need.
The obesity and metabolic syndrome management space is the subject of intense clinical development and interest in the medical community. ThermoStem® will provide physicians with a therapeutic alternative to drugs with a different mechanism of action currently on the market. with Altimmune (NASDAQ: ALT), Eli Lilly Co (NYSE: LLY) and Pfizer Inc (NYSE: PFE) looking to emulate the success of Semaglutide, marketed by Novo Nordisk A/S (NYSE: NVO) for the treatment of obesity and type 2 diabetes. Semaglutide was FDA-approved in 2021 for “chronic weight management” and was the first drug approved for this indication since 2014. Because ThermoStem® is a biologic rather than a synthetic drug, it might be a safer alternative to drugs currently under development that have demonstrated safety issues, such as Altimmunes (NASDAQ: ALT) weight loss drug that demonstrated gastrointestinal side effects when used.
Obesity: A Global Epidemic
Type 1 and type 2 diabetes are two distinct forms of the same disease. Type 1 is an autoimmune disease, whereas type 2 is linked to lifestyle factors such as poor diet and lack of exercise resulting in obesity.
Type 2 diabetes is caused by excess weight, poor diet and lack of exercise, leading to too much glucose (sugar) in the bloodstream. Cells in the body cannot respond as they would normally by removing glucose from the blood, a condition called insulin resistance. Type 2 diabetes can often be managed through diet and lifestyle changes such as eating a balanced diet, exercising regularly and maintaining a healthy weight. However, some people with type 2 diabetes may also need medication or insulin injections to manage their condition. Regardless of the type of diabetes, increased blood sugar can cause diseases of the heart, eyes and kidneys and may result in infection and amputation of the feet.
The health economic burden of obesity and type 2 diabetes is profound. According to the Centers for Disease Control and Prevention (CDC), over 37 million Americans have diabetes (about 1 in 10), with up to 95% having type 2 diabetes. Type 2 diabetes has historically been considered a disease of adults; however, given the current obesity epidemic, it is becoming more common in children, adolescents and younger adults. By 2030, over one billion individuals will be obese, with 1 in 7 men and 1 in 5 women living with the condition. The World Health Organization has designated obesity as a global epidemic.
The total annual cost of diabetes in the United States exceeds $327 billion. This includes direct medical costs, such as hospitalizations and medications, and indirect costs, from lost productivity due to illness or premature death.
The burden of obesity and type 2 diabetes is not limited to economic factors alone. The impact of these conditions on the quality of life for patients and carers can be immense. People living with obesity and diabetes are at greater risk for physical, mental, social and emotional difficulties stemming from their condition. Mental health disorders such as anxiety and depression are common among people living with these conditions, partly due to the discrimination they can experience. Physical disability is also an issue for many people living with these conditions. The emotional toll of living with a chronic illness can be immense, leading to feelings of isolation, fear and frustration.
ThermoStem® could potentially help with this burden through its novel approach. The novelty of the ThermoStem® technology was acknowledged by the United States Patent Office’s The Notice of Allowance was issued on February 24th of 2023. By expanding the ThermoStem® patent family with another issued patent, BioRestorative is positioned to further strengthen and secure its novel cell-based approach to treat obesity
Visit https://www.biorestorative.com for more information on the company and its product candidates.
This article was originally published on Benzinga.
BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.Today, BioRestorative is actively developing programs that aim to dramatically increase quality of care for both (i) chronic back pain caused by disc degeneration, as well as (ii) metabolic disorders including obesity and diabetes.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Contact Details
Investor Relations
